© The Author 2006. Published by Oxford University Press.
|
|
ARTICLE |
Statin Use and Breast Cancer: Prospective Results From the Women's Health Initiative
For the Women's Health Initiative Research Group
Affiliations of authors: Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA (JAC); Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (AM, RJR, AL); Departments of Medicine and Epidemiology and Biostatistics, University of California at San Francisco, CA (DCB); Berman Center for Outcomes and Clinical Research, Hennepin County Medical Center, Minneapolis, MN (KLM); Comprehensive Cancer Center, School of Public Health, The Ohio State University, Columbus, OH (EDP); School of Medicine, Department of Public Health Sciences, Wake Forest University, Winston-Salem, NC (MZV, CDF); Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA (RTC)
Correspondence to: Jane A. Cauley, DrPH, University of Pittsburgh, 130 DeSoto St., Crabtree Hall A524, Pittsburgh, PA 15261 (e-mail: jcauley{at}pitt.edu).
Background: Despite experimental observations suggesting that 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins) have antitumor activity, clinical studies have reached mixed conclusions about the relationship between statin use and breast cancer risk. Methods: To investigate associations between potency, duration of use, and type of statin used and risk of invasive breast cancer, we examined data for 156 351 postmenopausal women who were enrolled in the Women's Health Initiative. Information was collected on breast cancer risk factors and on the use of statins and other lipid-lowering drugs. Cox proportional hazards regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs). Statistical tests were two-sided. Results: Over an average follow-up of 6.7 years, 4383 invasive breast cancers were confirmed by medical record and pathology report review. Statins were used by 11 710 (7.5%) of the cohort. Breast cancer incidence was 4.09 per 1000 person-years (PY) among statin users and 4.28 per 1000 PY among nonusers. In multivariable models, the hazard ratio of breast cancer among users of any statin, compared with nonusers, was 0.91 (95% CI = 0.80 to 1.05, P = .20). There was no trend in risk by duration of statin use, with HR = 0.80 (95% CI = 0.63 to 1.03) for <1 year of use, HR = 0.99 (95% CI = 0.80 to 1.23) for 1–<3 years of use, and HR = 0.94 (95% CI = 0.75 to 1.18) for 
3 years of use. Hydrophobic statins (i.e., simvastatin, lovastatin, and fluvastatin) were used by 8106 women, and their use was associated with an 18% lower breast cancer incidence (HR = 0.82, 95% CI = 0.70 to 0.97, P = .02). Use of other statins (i.e., pravastatin and atorvastatin) or nonstatin lipid-lowering agents was not associated with breast cancer incidence. Conclusions: Overall statin use was not associated with invasive breast cancer incidence. Our finding that use of hydrophobic statins may be associated with lower breast cancer incidence suggests possible within-class differences that warrant further evaluation.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. R. Farwell, R. E. Scranton, E. V. Lawler, R. A. Lew, M. T. Brophy, L. D. Fiore, and J. M. Gaziano The Association Between Statins and Cancer Incidence in a Veterans Population J Natl Cancer Inst, January 16, 2008; 100(2): 134 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Hall, S. T. Page, T. G. Travison, R. B. Montgomery, C. L. Link, and J. B. McKinlay Do Statins Affect Androgen Levels in Men? Results from the Boston Area Community Health Survey Cancer Epidemiol. Biomarkers Prev., August 1, 2007; 16(8): 1587 - 1594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kotamraju, C. L. Willams, and B. Kalyanaraman Statin-Induced Breast Cancer Cell Death: Role of Inducible Nitric Oxide and Arginase-Dependent Pathways Cancer Res., August 1, 2007; 67(15): 7386 - 7394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Zhang, J. Lin, N. R. Cook, I-M. Lee, J. E. Manson, J. E. Buring, and P. M. Ridker C-Reactive Protein and Risk of Breast Cancer J Natl Cancer Inst, June 6, 2007; 99(11): 890 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Boudreau, O. Yu, D. L. Miglioretti, D. S.M. Buist, S. R. Heckbert, and J. R. Daling Statin Use and Breast Cancer Risk in a Large Population-Based Setting Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 416 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Brophy Pravastatin and cancer: an unproven association Can. Med. Assoc. J., February 27, 2007; 176(5): 646 - 647. [Full Text] [PDF]
|
|
|
|
|
|
P. F. Coogan, J. Smith, and L. Rosenberg Statin Use and Risk of Colorectal Cancer J Natl Cancer Inst, January 3, 2007; 99(1): 32 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Setoguchi, R. J. Glynn, J. Avorn, H. Mogun, and S. Schneeweiss Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly Circulation, January 2, 2007; 115(1): 27 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Sivaprasad, T. Abbas, and A. Dutta Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol. Cancer Ther., September 1, 2006; 5(9): 2310 - 2316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Do Statins Lower Cholesterol and Prevent Breast Cancer? Journal Watch Women's Health, June 20, 2006; 2006(620): 10 - 10. [Full Text]
|
|